Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders

Report Code: PHM118B

Publish Date: Oct 2023

Publisher: BCC Publishing

Category: Pharmaceuticals

Download Report Overview

Single User License: $5500

Member Price: FREE

Explore Our Services

Already a member? Login to access this report free.

Report Highlights

The global progressive ataxia and weakness disorders market reached $32.0 billion in 2022, should reach $35.1 billion by 2023 and $57.2 billion by 2028 with a compound annual growth rate (CAGR) of 10.2% during the forecast period of 2023-2028.

Report Includes

  • 34 data tables and 34 additional tables
  • An overview of the current and future global markets for the treatments of progressive ataxia and weakness disorders
  • Analyses of the global market trends, with historical market revenue data (sales figures) for 2022, estimates for 2023, forecasts for 2024 and 2026, and projections of compound annual growth rates (CAGRs) through 2028
  • In-depth information (facts and figures) pertaining to the major factors influencing the market, including growth trends, upcoming technologies and future prospects
  • An estimate of the actual market size, a revenue forecast for the market, and a market share analysis based on product, technology, disease type, application, distribution channel and region
  • A discussion of the applications for treatment and therapy technologies
  • Identification of critical medical and geographical challenges as well as economic and demographic factors affecting the market
  • A review of patent activity pertaining to applications for neurodegenerative disorders in the pharmaceutical and biotechnology markets
  • Coverage of recent mergers and acquisitions (M&A) activity, venture fundings and other developments affecting the global market
  • An analysis of the competitive landscape based on recent developments, segmental revenues and operational integration of the leading companies
  • Profiles of the major players in the industry

Report Scope

The scope of this study encompasses the neurodegenerative (i.e., progressive ataxia and weakness) disorders in the pharmaceutical and biotechnology markets. BCC analyzes each market and its applications, the technologies involved, market projections and market shares. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes India, China, Japan, Canada and Australia. The report informs all market players, potential entrants, government agencies and other interested parties. As the report covers geographic regions in detail, companies interested in expanding geographic reach will also find this helpful.

This report also covers merger and acquisition (M&A) strategies and collaborations, as well as the strengths and weaknesses of each strategy type.

Report Synopsis

Report Metrics Details
Base year considered 2022
Forecast period considered 2023-2028
Base year market size $32.0 billion
Market size forecast $57.2 billion
Growth rate CAGR of 10.2% for the forecast period of 2023-2028
Units considered $ Millions
Segments covered Technology, Disease Type, Disease, Distributive Channel,
Regions covered North America, Europe, Asia-Pacific, Rest of the World (RoW)
Key Market Drivers
  • Progressive Ataxia and Weakness: Increasing Prevalence and Awareness
  • Technological Advancements and Product Launch
  • Increasing Expenditures for Health Care
  • Rise in Alcohol and Drug Use
Companies studied
ABBOTTACORDA THERAPEUTICS
AMERICAN REGENT INC.APOTEX INC.
APOTHECA INC.ASTELLAS PHARMA INC.
ASTRAZENECABAXTER
BRISTOL-MYERS SQUIBB CO.EISAI CO. LTD.
LILLYGILEAD SCIENCES INC.
GSK PLC.GLENMARK LIFE SCIENCES
JOHNSON & JOHNSON SERVICES INC.MERCK KGAA
NOVARTIS AGPFIZER INC.
F. HOFFMANN-LA ROCHE LTD.SANOFI
TAKEDA PHARMACEUTICAL CO. LTD.TEVA PHARMACEUTICAL INDUSTRIES LTD.
Need a custom data table, graph, region, segment, companies or complete report? CUSTOMIZE NOW

Frequently Asked Questions (FAQs)

The progressive ataxia and weakness disorders drug market is projected to grow from $32.0 billion in 2022 to $57.2 billion in 2028, at a compound annual growth rate (CAGR) of 10.2 % during the forecast period.
The key factors driving the growth of treatments for syndromes of progressive ataxia and weakness disorders- Global Market include:
  • Increasing Prevalence of Neurological Disorders including Progressive Ataxia and Weakness Disorders and Awareness
  • Technological advancements and product launch
  • Increasing Expenditures for Health Care and investments for treatment for syndrome of Progressive Ataxia and Weakness Disorders
  • Rise in alcohol and drug usage
In this report, the market is segmented based on type, technology, diseases, region and distributive channel. Based on the type, the market is segmented into progressive ataxia and progressive weakness disorders. Based on the technology, the market is segmented as small molecule, monoclonal antibody and others. Based on diseases, progressive ataxia is segmented as Friedreich ataxia, Machado Joseph disease/SCA3 and Gertsmann Straussler Scheinker diseases and progressive weakness disorders as multiple sclerosis, hereditary neuropathies, amyotrophic lateral sclerosis, progressive bulbar palsy and hereditary spastic paraplegia. Based on distributive channel, the market is segmented into retail pharmacy, hospital pharmacy and online pharmacy.
Progressive weakness disorders will dominate the market by the end of 2028.
The major players in the market are Novartis AG, Pfizer Inc., Sanofi, Roche Holding Ltd. And Teva Pharmaceuticals.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

Let us assist you! Our analysts are ready to tailor this report to your specific need. REACH OUT TO US TODAY

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders180Free
Chapter- 1: Introduction8Free
Chapter- 2: Summary and Highlights5Free
Chapter- 3: Market Overview7Free
Chapter- 4: Market Dynamics8Free
Chapter- 5: Market Breakdown by Type and Technology14Free
Chapter- 6: Market Breakdown by Disease22Free
Chapter- 7: Market Breakdown by Region21Free
Chapter- 8: Market Breakdown by Distribution Channel6Free
Chapter- 9: Emerging Technologies and Developments5Free
Chapter- 10: ESG Development11Free
Chapter- 11: Patent Analysis6Free
Chapter- 12: M&A and Venture Funding Outlook and Competitive Landscape7Free
Chapter- 13: Company Profiles56Free
Chapter- 14: Appendix: Abbreviations4Free
Published - Oct-2012| Analyst - Shalini Shahani Dewan| Code - PHM118A

Report Highlights

The global market for treatments for syndromes of progressive ataxia and weakness disorders was valued at nearly $14 billion in 2011 and should reach nearly $15 billion in 2012. Total market value is expected to reach nearly $23.5 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 9.4%.

Related Reports

Central Nervous System (CNS) Biomarkers: Technologies and Global Markets

Published - May 2023 | Publisher - BCC Publishing | Code - BIO074D

The global central nervous system (CNS) biomarkers market should reach $9.5 billion by 2027 from $5.7 billion in 2022 at a compound annual growth rate (CAGR) of 10.8% for the forecast period of 2022 to 2027.

Global Markets for Bioengineered Protein Drugs

Published - Apr 2023 | Publisher - BCC Publishing | Code - BIO009H

The global market for bioengineered protein drugs is estimated to increase from $354.1 billion in 2022 to reach $521.3 billion by 2027, at a compound annual growth rate (CAGR) of 8.0% from 2022 through 2027.

Immunotherapy Drugs: Global Markets

Published - Apr 2021 | Publisher - BCC Publishing | Code - PHM249A

The global market for immunotherapy drugs should grow from $139.8 billion in 2020 to $204.4 billion by 2025, at compound annual growth rate (CAGR) of 7.9% for the period of 2020-2025.

Global Markets for Enzyme Inhibitors

Published - Jan 2018 | Publisher - Shalini Shahani Dewan | Code - BIO057C

The global market for enzyme inhibitors should reach $179.9 billion by 2022 from $168 billion in 2017 at a compound annual growth rate (CAGR) of 1.4%, from 2017 to 2022.

Recent Reports

Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets

Published - Apr 2024 | Publisher - BCC Publishing | Code - PHM046D

The global market for gastrointestinal (GI) therapeutics and diagnostics is expected to grow from $86.0 billion in 2023 and projected to reach $122.5 billion by the end of 2028, at a compound annual growth rate (CAGR) of 7.3% during the forecast period of 2023 to 2028.

Global Markets and Technologies for Advanced Drug Delivery Systems

Published - Mar 2024 | Publisher - BCC Publishing | Code - PHM006N

The global market for advanced drug delivery systems is expected to increase from $262.6 billion in 2023 to $359.1 billion by the end of 2028, with a compound annual growth rate (CAGR) of 6.5% during the forecast period of 2023-2028.

Prevention and Treatment of Prostate Cancer: Technologies and Global Markets

Published - Feb 2024 | Publisher - BCC Publishing | Code - PHM113C

The global market for prostate cancer care is expected to grow from $37.9 billion in 2023 to $56.4 billion by the end of 2028, at a compound annual growth rate (CAGR) of 8.3% from 2023 through 2028.

Global Markets for Vaccine Technologies

Published - Feb 2024 | Publisher - BCC Publishing | Code - PHM014K

The global market for vaccine technologies is expected to grow from $45.0 billion in 2023 to $65.3 billion by the end of 2028, at a compound annual growth rate (CAGR) of 7.8% from 2023 to 2028.

Chagas Disease: American trypanosomiasis Market

Published - Feb 2024 | Publisher - BCC Publishing | Code - PHM282A

The report provides detailed coverage of the Chagas Disease market. It analyzes the market trends and epidemiology of CD, and the regional markets of CD. It highlights the current market for CD and gives a detailed analysis of the competitive environment. The report depicts the complete scenario of Chagas Disease, types of parasites that cause human African trypanosomiasis (HAT) and its presence in various regions of the world.

Top Trending Reports

Cell and Gene Therapy Tools, and Reagents: Global Markets

Published - Nov 2022 | Publisher - BCC Publishing | Code - BIO208B

The global market for cell and gene therapy tools and reagents is estimated to grow from $8.3 billion in 2022 to $13.7 billion in 2027, with a compound annual growth rate (CAGR) of 10.6% for the period of 2022-2027.

World Markets for Fermentation Ingredients

Published - Nov 2022 | Publisher - BCC Publishing | Code - FOD020G

The global fermentation-derived fine chemicals market should reach $42.4 billion by 2027 from $32.0 billion in 2022 at a compound annual growth rate (CAGR) of 5.8% for the forecast period of 2022 to 2027.

Digital Pathology: Technologies and Global Markets

Published - Dec 2022 | Publisher - BCC Publishing | Code - HLC161D

The global digital pathology market is estimated to increase from $5.9 billion in 2022 to reach $10.7 billion by 2027, at a compound annual growth rate (CAGR) of 12.5% from 2022 through 2027.

Smartphone-Based Patient Monitoring: Global Market

Published - Nov 2022 | Publisher - BCC Publishing | Code - HLC285A

The global smartphone-based patient monitoring market should reach $21.5 billion by 2027 from $6.8 billion in 2022 at a compound annual growth rate (CAGR) of 25.9% for the forecast period of 2022 to 2027.

Seawater and Brackish Water Desalination

Published - Nov 2022 | Publisher - BCC Publishing | Code - MST052E

The global market for seawater and brackish water desalination is estimated to increase from $14.7 billion in 2022 to $21.7 billion by 2027, at a compound annual growth rate (CAGR) of 8.1% from 2022 through 2027.

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders
Sample Report